

**Intercell AG**  
**Document according to section 75a of the Austrian Stock Exchange Act (SEA)**  
**of mandatory announcements during the fiscal year 2006**

<b>Date</b>	<b>Type</b>	<b>Description</b>	<b>Source</b>
09.01.2006	Ad-hoc announcement	Announcement of the receipt of a €1 million milestone payment from partner sanofi pasteur for progress on a bacterial vaccine candidate	www.intercell.com
12.01.2006	Ad-hoc announcement	Announcement of positive safety evaluation of Intercell's Japanese Encephalitis vaccine in Phase III trials	www.intercell.com
30.01.2006	Ad-hoc announcement	Announcement of the grant of Orphan Drug status for Intercell's Japanese Encephalitis Vaccine by the European Commission	www.intercell.com
31.01.2006	Ad-hoc announcement	Announcement of positive study results for Intercell's Hepatitis C vaccine: success criteria for further development met - route and frequency of administration optimized	www.intercell.com
03.02.2006	Ad-hoc announcement	Announcement of changes in the Supervisory Board: Resignation of Luke Evnin	www.intercell.com
14.02.2006	Ad-hoc announcement	Announcement of the appointment of a new scientific advisory board	www.intercell.com
21.02.2006	Ad-hoc announcement	Announcement of the completion of enrollment for Phase III study of the Japanese Encephalitis Vaccine	www.intercell.com
06.03.2006	Zwischenbericht, ad-hoc announcement	Announcement of preliminary full year results 2005	www.intercell.com
30.03.2006	Announcement according to section 93 SEA	Changes in shares of voting rights: MPM Bio Ventures III-QP L.P. holds less than 10 % of the voting rights	Wiener Zeitung
06.04.2006	Ad-hoc announcement	Announcement of a strategic alliance with Kirin Pharmaceutical to develop antibodies for the treatment of severe pneumococcal infections	www.intercell.com
08.04.2006	Announcement according to section 93 SEA	Changes of the shares in voting rights: Funds managed by MPM Capital L.P. hold less than 10 % of the voting rights	Wiener Zeitung

<b>Date</b>	<b>Type</b>	<b>Description</b>	<b>Source</b>
20.04.2006	Group / Statutory Annual Financial Statements	Publication of the Annual Report 2005	www.intercell.com, paying agent Erste Bank
20.04.2006	AGM invitation	Invitation for the Annual General Meeting held on May 12, 2006	Wiener Zeitung
20.04.2006	Report according to sec. 98 (3) and 159 (2) lit 3 Stock Corporations Act	Report of the Management Board on the grant of stock options to the members of the Supervisory Board	Wiener Zeitung
22.04.2006	AGM invitation	Amendment to the agenda of the Annual General Meeting held on May 12, 2006	Wiener Zeitung
26.04.2006	Ad-hoc announcement	Announcement of grant of an European Patent for Intercell's synthetic adjuvant IC31TM	www.intercell.com
08.05.2006	Interim report, ad-hoc announcement	Interim report for the first quarter 2006	www.intercell.com, paying agent Erste Bank
11.05.2006	Ad-hoc announcement	Announcement of a strategic alliance with Merck for the development of monoclonal antibodies for the treatment of severe Staphylococcus aureus infections	www.intercell.com
15.05.2006	Ad-hoc announcement	Announcement of changes in the Supervisory Board: Appointment of Hans Wigzell and Mustafa L. Bakali	www.intercell.com
31.05.2006	Ad-hoc announcement	Announcement of positive clinical trial results for the Japanese Encephalitis virus vaccine in pivotal Phase III study meets primary endpoint	www.intercell.com
13.06.2006	Ad-hoc announcement	Announcement of a marketing and distribution agreement with Novartis for the Japanese Encephalitis Vaccine	www.intercell.com
13.06.2006	Ad-hoc announcement	Announcement of the launch of a combined primary and secondary public offering of up to 7.8 million shares	www.intercell.com

<b>Date</b>	<b>Type</b>	<b>Description</b>	<b>Source</b>
13.06.2006	Prospectus according to section 2 (1)	Prospectus, dated June 30, 2006	Österreichische Kontrollbank AG
14.06.2006	Announcement according to section 10 Capital Markets Act	Announcement of the publication of a report according to section 10 Capital Markets Act	Wiener Zeitung
14.06.2006	Announcement	Request to exercise subscription rights for the issuance of 4.736.835 new shares at a subscription ratio of 7:1 from 14.6.2006 to 28.6.2006	Wiener Zeitung
30.06.2006	Ad-hoc announcement	Announcement of the successful completion of the combined primary and secondary public offering at a subscription and issue price of €12.36 per share	www.intercell.com
01.07.2006	Announcement according to section 7(5) and 10(3) Z 1 Capital Markets Act	Announcement of the final subscription and issue price and offering volume for the issuance of 4.736.835 new shares and 3.068.165 existing shares	Wiener Zeitung
07.07.2006	Ad-hoc announcement	Announcement of the full exercise of the over-allotment option in connection with the public offering of shares dated June 13, 2006	www.intercell.com
12.07.2006	Announcement according to section 93 SEA	Changes in the shares of voting rights: Funds managed by MPM Capital L.P. and Nomura International plc each hold less than 5 % of the voting rights, V-Sciences Investments Pte ltd and Novartis Vaccines and Diagnostics Inc. each hold more than 5 % of the voting rights	Wiener Zeitung
03.08.2006	Ad-hoc announcement	Announcement of the recruitment of Thomas Lingelbach	www.intercell.com
14.08.2006	Interim report, ad-hoc announcement	Interim report for the second quarter / first half of 2006	www.intercell.com, paying agent Erste Bank

<b>Date</b>	<b>Type</b>	<b>Description</b>	<b>Source</b>
24.08.2006	Ad-hoc announcement	Announcement of positive safety results from phase III trials for the Japanese Encephalitis Vaccine	www.intercell.com
06.09.2006	Ad-hoc announcement	Announcement of a collaboration with PATH for the development of Intercell's Streptococcus pneumoniae vaccine	www.intercell.com
12.09.2006	Ad-hoc announcement	Announcement of a strategic partnership with Wyeth for the use of its IC31™ adjuvant in various selected infectious disease vaccines	www.intercell.com
26.09.2006	Ad-hoc announcement	Announcement of the start of a next Phase II clinical trial for the therapeutic Hepatitis C vaccine (IC41) a	www.intercell.com
26.09.2006	Announcement (section 7 <i>VöffVO</i> )	Announcement on the sale of treasury shares in connection with the exercise of employee stock options	www.intercell.com
02.10.2006	Ad-hoc announcement	Announcement of changes in the Supervisory Board: Resignation of Helmuth Schühlsler, appointment of Michel Gréco as chairman	www.intercell.com
12.10.2006	Ad-hoc announcement	Announcement of the start of the regulatory process for the Japanese Encephalitis Vaccine with the U.S. Food and Drug Administration (FDA)	www.intercell.com
26.10.2006	Ad-hoc announcement	Announcement of the expansion of the strategic alliance with Merck for the development of a prophylactic vaccine and antibody treatments against Group A Streptococcus infections	www.intercell.com
03.11.2006	Announcement according to section 93 SEA	Changes in the share of voting rights: Funds managed by TVM Capital GmbH hold less than 5 % of the voting rights	Wiener Zeitung
13.11.2006	Interim report, ad-hoc announcement	Interim report for the third quarter of 2006	www.intercell.com, paying agent Erste Bank

<b>Date</b>	<b>Type</b>	<b>Description</b>	<b>Source</b>
06.12.2006	Ad-hoc announcement	Announcement of the intended acquisition of Pelias Biomedizinische Entwicklungs AG	www.intercell.com
12.12.2006	Ad-hoc announcement	Announcement of study results for the therapeutic Hepatitis C vaccine, which was safe in combination with standard therapy	www.intercell.com
16.12.2006	Report according to section 159(3) and (2) Z 3 Stock Corporation Act	Report of the management board according to section 159(3) and (2) Z 3 Stock Corporation Act on the issuance of stock options to members of the management board, key employees and employees	Wiener Zeitung
19.12.2006	Ad-hoc announcement	Announcement of promising results for prophylactic Staphylococcus aureus subunit vaccine	www.intercell.com